


Novel index predicts survival after chemo in pancreatic cancer

16 May 2016



(HealthDay)—For patients with advanced pancreatic cancer receiving chemotherapy, the systemic inflammation response index (SIRI), based on peripheral neutrophil, monocyte, and lymphocyte counts, can predict survival, according to a study published online May 6 in *Cancer*.

Qi Qi, M.D., from the Fudan University Shanghai Cancer Center, and colleagues developed the SIRI in a training set of 177 [patients](#) with advanced pancreatic cancer who had received [palliative chemotherapy](#). The predictive ability was validated in two independent cohorts with 397 patients.

The researchers found that in the training cohort, patients with a SIRI ≥ 1.8 had a shorter time to progression (TTP) than patients with a SIRI

APA citation: Novel index predicts survival after chemo in pancreatic cancer (2016, May 16) retrieved 10 June 2021 from <https://medicalxpress.com/news/2016-05-index-survival-chemo-pancreatic-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.